multiple sclerosis

News

Laquinimod failure is bad news for Teva's MS hopes

Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.

News

Biogen shares up after strong launch for rare disease drug

US insurers are covering the treatment, despite high price.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA approves two biggest new drugs of 2017

Sales of MS and eczema drugs could top $4bn by 2022

News

Apitope aims to bounce back from MS setback

Biotech looks for funding and long-term development partner

News

Celgene to file potential MS blockbuster this year

Success with ozanimod would justify $7.2 billion outlay for Receptos.

News

Teva's CEO Vigodman steps down

Firm searches for new leader, chairman takes over on interim basis.

Laquinimod failure is bad news for Teva's MS hopes

Biogen shares up after strong launch for rare disease drug

FDA approves two biggest new drugs of 2017

Apitope aims to bounce back from MS setback

Celgene to file potential MS blockbuster this year

Teva's CEO Vigodman steps down

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

multiple sclerosis

Editor's Picks